21 results on '"Kukreti V"'
Search Results
2. Outcomes in Stage I-II Diffuse Large B-Cell Lymphoma Presenting With Extradural Involvement at a Single Centre (1995-2010)
3. Long Term Cryopreserved Autologous Blood Stem Cells For Salvage Autologous Stem Cell Transplantation (ASCT) in Relapsed Multiple Myeloma (MM) Patients
4. A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)
5. Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)
6. Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years
7. A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)
8. A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens
9. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM)
10. Pattern of Failure in Patients With Stage I-II Hodgkin Lymphoma Treated With CMT: Implications of Partial Nodal Region Coverage and the Need for Adjacent Uninvolved Nodal Region Coverage
11. A Single Institution Experience of Extranodal Natural Killer/T-cell Lymphoma of Nasal Type
12. 9219 POSTER Combined Modality Therapy for Stage l-ll Diffuse Large B-cell Lymphoma Provides Excellent Local Control and Clinical Outcome in the Rituximab Era
13. Positron Emission Tomography for Response Assessment of Lymphoma Patients Having Residual Abnormalities following Initial Treatment: The Impact on Clinical Management
14. 9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma
15. 9201 Tolerability profile of carfilzomib enables full-dose anti-tumor treatment for up to 12 months
16. A493 Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (PX-171-004)
17. A334 Bortezomib-Based Therapy Following Prior Lenalidomide + Dexamethasone in Relapsed Multiple Myeloma
18. A378 Phase II Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004)
19. A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM
20. A458 Retropective Comparison of Engraftment After First and Second Autotransplantations for Relapsed Myeloma
21. Synthesis and spectra of some new phthalein dyes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.